673 - Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA): Results from a multi-national, multicenter observational study

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

AS

Alex Soriano, MD

Infectious Disease
Hospital Clínic de Barcelona
Barcelona, Catalonia, Spain
LP

Laura A. Puzniak, MPH, PhD

Global Director, Outcomes Research
Merck & Co
New York, New York, United States
David Paterson, MBBS

Director, UQCCR
The University of Queensland
Brisbane, Queensland, Australia
FT

Florian Thalhammer, MD

Infectious Disease specialist
Medizinische Universität Wien
Vienna, Wien, Austria
SK

Stefan Kluge, MD

University Medical Center Hamburg-Eppendorf
Martinistrasse, Hamburg, Germany
PV

Pierluigi Viale, n/a

MD
Infectious Diseases Unit, Department of Medical and Surgical Sciences, Policlinico Sant'Orsola Malpighi, University of Bologna, Bologna, Italy
Bologna, Emilia-Romagna, Italy
AW

Alexandre H. Watanabe, PharmD

Merck & Co., Inc.
South Orange, New Jersey, United States

Engels N. Obi, PhD

Director Outcomes Research
Merck & Co., Inc
BASKING RIDGE, New Jersey, United States